Loading
A phase 3 trial of Atirmociclib, Abemaciclib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Pfizer, active and no longer recruiting.
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease is a phase 3 interventional study registered as NCT06760637 by Pfizer, with 1035 participants enrolled, started 2025-01-06 and due to reach its primary completion in 2029-01-02. Interventions recorded: PF-07220060, letrozole, abemaciclib, palbociclib and ribociclib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atirmociclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/